Proportional hazards modeling of risk of CMV reactivation after allogeneic HSCT, stratified by stem cell source (PBSC vs BM)
| Characteristic . | Univariate HR (95% CI) . | P . | Multivariate HR (95% CI) . | P . |
|---|---|---|---|---|
| Donor/recipient CMV serostatus | < .001 | |||
| CMV D-/R- | 1 | — | 1 | — |
| CMV D+/R- | 1.867 (1.204-2.894) | — | 2.016 (1.292-3.146) | .002 |
| CMV D+/R+ | 3.476 (2.343-5.159) | — | 4.176 (2.762-6.315) | < .001 |
| CMV D-/R+ | 5.210 (3.634-7.468) | — | 5.655 (3.873-8.257) | < .001 |
| Recipient race: non white | 2.659 (1.808-3.910) | < .001 | 1.434 (0.924-2.223) | .11 |
| Conditioning: reduced-intensity | 0.802 (0.610-1.054) | .11 | 0.738 (0.487-1.121) | .15 |
| HLA matching: mismatched donor | 1.545 (1.057-2.258) | .025 | 1.243 (0.813-1.899) | .32 |
| Donor relatedness: unrelated donor | 1.391 (1.067-1.813) | .015 | 1.138 (0.834-1.553) | .42 |
| Stem cell source: peripheral blood | 0.655 (0.501-0.855) | .002 | —† | — |
| Transplantation period | ||||
| 4/2000-6/2001 | 1 | — | 1 | — |
| 7/2001-6/2002 | 0.708 (0.495-1.013) | .06 | 1.108 (0.709-1.729) | .65 |
| 7/2002-6/2003 | 0.570 (0.394-0.825) | .003 | 0.746 (0.444-1.254) | .27 |
| 7/2003-6/2004 | 0.688 (0.485-0.977) | .036 | 1.005 (0.598-1.690) | .98 |
| Acute GVHD*: grades II-IV | 1.532 (1.159-2.025) | .003 | 1.518 (1.088-2.118) | .01 |
| GVHD prophylaxis regimen | ||||
| Cyclosporine | 1.275 (0.941-1.729) | .12 | 1 | — |
| Tacrolimus alone | 1.212 (0.922-1.592) | .17 | 0.664 (0.391-1.127) | .14 |
| Sirolimus + tacrolimus | 0.672 (0.511-0.885) | .005 | 0.455 (0.266-0.779) | .004 |
| Prednisone | 1.140 (0.822-1.580) | .43 | 1.270 (0.706-2.286) | .42 |
| Methotrexate | 1.258 (0.953-1.660) | .10 | 1.741 (1.072-2.827) | .02 |
| Mycophenolate mofetil | 1.190 (0.752-1.884) | .46 | 1.056 (0.584-1.907) | .86 |
| T-cell depletion | 1.081 (0.732-1.596) | .67 | 1.136 (0.662-1.952) | .64 |
| Characteristic . | Univariate HR (95% CI) . | P . | Multivariate HR (95% CI) . | P . |
|---|---|---|---|---|
| Donor/recipient CMV serostatus | < .001 | |||
| CMV D-/R- | 1 | — | 1 | — |
| CMV D+/R- | 1.867 (1.204-2.894) | — | 2.016 (1.292-3.146) | .002 |
| CMV D+/R+ | 3.476 (2.343-5.159) | — | 4.176 (2.762-6.315) | < .001 |
| CMV D-/R+ | 5.210 (3.634-7.468) | — | 5.655 (3.873-8.257) | < .001 |
| Recipient race: non white | 2.659 (1.808-3.910) | < .001 | 1.434 (0.924-2.223) | .11 |
| Conditioning: reduced-intensity | 0.802 (0.610-1.054) | .11 | 0.738 (0.487-1.121) | .15 |
| HLA matching: mismatched donor | 1.545 (1.057-2.258) | .025 | 1.243 (0.813-1.899) | .32 |
| Donor relatedness: unrelated donor | 1.391 (1.067-1.813) | .015 | 1.138 (0.834-1.553) | .42 |
| Stem cell source: peripheral blood | 0.655 (0.501-0.855) | .002 | —† | — |
| Transplantation period | ||||
| 4/2000-6/2001 | 1 | — | 1 | — |
| 7/2001-6/2002 | 0.708 (0.495-1.013) | .06 | 1.108 (0.709-1.729) | .65 |
| 7/2002-6/2003 | 0.570 (0.394-0.825) | .003 | 0.746 (0.444-1.254) | .27 |
| 7/2003-6/2004 | 0.688 (0.485-0.977) | .036 | 1.005 (0.598-1.690) | .98 |
| Acute GVHD*: grades II-IV | 1.532 (1.159-2.025) | .003 | 1.518 (1.088-2.118) | .01 |
| GVHD prophylaxis regimen | ||||
| Cyclosporine | 1.275 (0.941-1.729) | .12 | 1 | — |
| Tacrolimus alone | 1.212 (0.922-1.592) | .17 | 0.664 (0.391-1.127) | .14 |
| Sirolimus + tacrolimus | 0.672 (0.511-0.885) | .005 | 0.455 (0.266-0.779) | .004 |
| Prednisone | 1.140 (0.822-1.580) | .43 | 1.270 (0.706-2.286) | .42 |
| Methotrexate | 1.258 (0.953-1.660) | .10 | 1.741 (1.072-2.827) | .02 |
| Mycophenolate mofetil | 1.190 (0.752-1.884) | .46 | 1.056 (0.584-1.907) | .86 |
| T-cell depletion | 1.081 (0.732-1.596) | .67 | 1.136 (0.662-1.952) | .64 |